🔬🟣
@GEICAM is already at
#ASCO2026, where these days have already been filled with many valuable and inspiring meetings, and day one has kicked off with two oral presentations from international collaborative research featuring authors from our group 👇
🔹NATALEE trial
This new analysis from the
#NATALEE trial evaluated the prognostic and predictive value of baseline gene expression in stage II/III HR /HER2- early
#breastcancer treated with adjuvant ribociclib plus a nonsteroidal aromatase inhibitor versus aromatase inhibitor alone 🧬 Following the previously reported invasive disease-free survival benefit with
#ribociclib, this subanalysis included more than 3,000 tumor samples assessed with the NanoString BC360 panel, including
#PAM50 molecular subtyping 💊 Ribociclib showed consistent benefit across all molecular subtypes, while greater benefit was observed in patients with higher genomic risk or proliferation, suggesting a potential role for gene expression profiling in future patient selection.
🔹lidERA BC clinical trial
This phase III study compared
#giredestrantwith standard endocrine therapy in pre- and postmenopausal women with stage I–III ER /HER2- early breast
#cancer previously treated with surgery and
#chemotherapy when indicated 🧫 In 4,170 patients, giredestrant improved invasive disease-free survival across both menopausal groups and reduced the risk of
#metastatic disease 📊 It also showed a comparable safety profile with fewer treatment discontinuations due to toxicity, particularly musculoskeletal pain, supporting its potential as an effective and better-tolerated alternative.
🙌 We are especially proud of the entire team who travelled to Boston, and particularly of Dr. Miguel Martín, founder of GEICAM and its President for 30 years until last year, whose contribution as an author to both studies reflects the long-standing commitment and dedication of our investigators to advancing
#GEICAM #BreastCancerResearch #ASCO26. 🙌🚀
@ASCO @ASCOPost @oncofir